We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A class of indirect purchasers filed an antitrust suit against Allergan over the transfer of its Restasis patents to the St. Regis Mohawk tribe and other anticompetitive practices that inflated the drug’s price. Read More
Pfizer reached a $94 million settlement with a class of direct purchasers over claims it used fraudulent patents to keep generic competition off the market for its anti-inflammatory drug Celebrex. Read More
An Ohio federal judge denied a new trial to plaintiffs in a lawsuit against Abbott Laboratories who claimed their son was born with birth defects because the company failed to warn of the risks associated with its anticonvulsant drug Depakote. Read More
The Supreme Court appeared divided Monday on the constitutionality of the PTO’s patent re-examination process of inter partes review — in a debate with wide implications for drugmakers on whether patents are considered private property and if they can only be invalidated through a trial by jury. Read More
The UK’s competition watchdog agency claimed the drugmaker Concordia overcharged the NHS by millions for its hypothyroid medication liothyronine, also known as Cytomel, following price increases of almost 6,000 percent over a decade. Read More
A federal judge blocked Aegerion’s proposed $36 million deal to settle claims of illegal marketing tactics for its cholesterol drug Juxtapid, ordering the case to trial. Read More
Genentech filed a lawsuit aiming to stop Pfizer’s proposed Herceptin biosimilar from reaching the market — asking the court to compensate for losses in sales should the copy launch before 2019, when several patents are set to expire. Read More